Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

December 31, 2015

Study Completion Date

February 28, 2018

Conditions
Malignant Pleural EffusionLung CancerMesotheliomaBreast CancerOvarian Cancer
Interventions
BIOLOGICAL

AdV-tk + valacyclovir

AdV-tk will be administered intrapleural through pleural catheter followed by oral valacyclovir. Valacyclovir will be administered orally at a fixed dose for 14 days after each AdV-tk administration.

Trial Locations (1)

19104

University of Pennsylvania, Philadelphia

Sponsors
All Listed Sponsors
collaborator

University of Pennsylvania

OTHER

lead

Candel Therapeutics, Inc.

INDUSTRY

NCT01997190 - Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion | Biotech Hunter | Biotech Hunter